On September 30, GENFLEET-B rose 5.27% in regular trading, trading at HKD 31.3/share with turnover of HKD 13.76 million, extending the prior session's rebound momentum.

On the news front, the company's oral KRAS G12D inhibitor GFH375, in combination with cetuximab for KRAS G12D-mutant metastatic colorectal cancer, has been proposed for inclusion on CDE's Breakthrough Therapy Designation (BTD) list. If approved through the public comment period, this would mark the third BTD for GFH375, following prior designations for non-small cell lung cancer and pancreatic cancer indications. Additionally, the company has executed 10 share buybacks year-to-date, repurchasing a cumulative 988,000 shares for approximately HKD 25.58 million, signaling management confidence.

A key near-term catalyst is the scheduled October 15 investor briefing, where preliminary clinical data for GFH375 combined with cetuximab in KRAS G12D-mutant solid tumors will be disclosed. Both BOCOM International and CITIC Securities maintain Buy ratings on the stock, citing a rich pipeline of clinical catalysts ahead.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)